for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DBV Technologies SA

DBV.PA

Latest Trade

5.33EUR

Change

0.03(+0.49%)

Volume

76,503

Today's Range

5.30

 - 

5.41

52 Week Range

3.91

 - 

13.69

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
5.30
Open
5.34
Volume
76,503
3M AVG Volume
9.87
Today's High
5.41
Today's Low
5.30
52 Week High
13.69
52 Week Low
3.91
Shares Out (MIL)
54.88
Market Cap (MIL)
286.19
Forward P/E
-3.10
Dividend (Yield %)
--

Next Event

DBV Technologies SA at Evercore ISI HealthCONx Virtual Conference

Latest Developments

More

Dbv Technologies Reports Third Quarter 2021 Financial Results And Recent Regulatory Developments

DBV Technologies Reports Q2 2021 Financial Results

DBV Technologies SA Files For Stock Shelf Of Up To $250 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About DBV Technologies SA

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Industry

Biotechnology & Drugs

Contact Info

177-181 avenue Pierre Brossolette

92120

France

+33.1.55427878

https://www.dbv-technologies.com/

Executive Leadership

Michel de Rosen

Non-Executive Independent Chairman of the Board

Daniel Tasse

Chief Executive Officer, Director

Sebastien Robitaille

Chief Financial Officer

Pharis Mohideen

Chief Medical Officer

Michele F. Robertson

Chief Legal Officer

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (EUR)

2018

-5.740

2019

-4.150

2020

-2.520

2021(E)

-1.834
Price To Earnings (TTM)
--
Price To Sales (TTM)
73.58
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

U.S. FDA declines to approve DBV Technologies' peanut allergy patch

French drug developer DBV Technologies SA said on Tuesday the U.S. health regulator declined to approve its experimental skin patch for peanut allergy in children, citing concerns about its effectiveness.

BRIEF-DBV Technologies Cash And Cash Equivalents As of March 31 Up At EUR 262.4 Mln

* AS OF MARCH 31, 2020, CASH AND CASH EQUIVALENTS EUR 262.4 MILLION VERSUS EUR 172.0 MILLION AS OF DEC 31, 2019 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-DBV Technologies Provides Update On Viaskin Peanut BLA For Children Ages 4-11 Years

* DBV TECHNOLOGIES PROVIDES UPDATE ON VIASKIN PEANUT BLA FOR CHILDREN AGES 4-11 YEARS

BRIEF-DBV Technologies: Potential Long-Term Benefit Of Viaskin Peanut

* ANNOUNCED ON SATURDAY THE COMPANY WILL PRESENT DATA FROM EPICUTANEOUS IMMUNOTHERAPY AT EAACI 2019

BRIEF-DBV Technologies FY Net Loss Widens To 166.1 Million Euros

* REPORTED ON TUESDAY FY SALES AND MARKETING EXPENSES EUR 32.2 MLN VS EUR 15.8 MLN YR AGO

BRIEF-DBV Technologies To Resubmit Biologics License Application For Viaskin Peanut In Q3 2019

* ANNOUNCED ON WEDNESDAY UPDATE ON REGULATORY STATUS OF VIASKIN PEANUT FOR THE TREATMENT OF PEANUT-ALLERGIC CHILDREN 4 TO 11 YEARS OF AGE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up